Arrowhead Pharmaceuticals (ARWR) Peer Comparison
$47.78
As on 13-Nov-2026 16:06EST
Market cap
$6,749 Mln
Revenue (TTM)
$451 Mln
P/E Ratio
--
P/B Ratio
14.3
Div. Yield
0 %
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6,749 | 16,837 | 18,064 | 11,432 | 10,891 |
Revenue ($ Mln) |
451 | 2,497 | 1,208 | 1,802 | 102 |
Net Profit ($ Mln) |
-724.21 | 885.14 | 890.37 | 485.42 | -349.47 |
Net Margin (%) |
-160.64 | 35.45 | 73.69 | 26.93 | -341.87 |
RoE (%) |
-280.50 | 46.96 | 88.40 | -- | -22.16 |
Price to Earnings |
-- | 20.66 | 18.11 | 25.19 | -- |
Price-To-Book |
14.31 | 9.18 | 10.44 | 97.15 | 6.72 |
Income Statement ($ Mln)
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
450.82 | -- | -- | -- | -- |
|
Cost of Revenue
|
1.80 | -- | -- | -- | -- |
|
Gross Profit
|
449.02 | -- | -- | -- | -- |
|
Operating Expenses
|
1,156.19 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-707.17 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-723.92 | -- | -- | -- | -- |
|
Provision for Tax
|
-6.78 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-724.21 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
50.31 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1,376.41 | -- | -- | -- | -- |
|
Current Liabilities
|
311.34 | -- | -- | -- | -- |
|
Total Liabilities
|
1,738.26 | -- | -- | -- | -- |
Assets ($ Mln)
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
449.04 | -- | -- | -- | -- |
|
Current Assets
|
1,289.22 | -- | -- | -- | -- |
|
Total Assets
|
1,738.26 | -- | -- | -- | -- |
|
Total Debt*
|
1,000.20 | -- | -- | -- | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-271.95 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-670.48 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
776.82 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-76.93 | -- | -- | -- | -- |
|
ROE (%)
|
-280.50 | -- | -- | -- | -- |
|
ROA (%)
|
-46.37 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-160.64 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.46 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-44,302.58 | -- | -- | -- | -- |
|
EPS Growth (%)
|
-425.46 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-12.77 | -- | -- | -- | -- |
|
Price / Book Value
|
183.80 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-15.00 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
19.88 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.90 | -- | -- | -- | -- |
|
Current Ratio
|
4.14 | -- | -- | -- | -- |
|
Quick Ratio
|
4.11 | -- | -- | -- | -- |
|
Interest Coverage
|
-6.73 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Arrowhead Pharmaceuticals (ARWR) | Exelixis (EXEL) | Ascendis Pharma A/S - ADR | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
2.20 | -- | -- | -- | -- |
|
Asset Turnover
|
0.29 | -- | -- | -- | -- |
|
Receivable days
|
6.79 | -- | -- | -- | -- |
|
Inventory Days
|
1,842.49 | -- | -- | -- | -- |
|
Payable days
|
4,854.74 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
-3,005.46 | -- | -- | -- | -- |